Primary post-surgical Pegvisomant treatment can be considered in patients after irradiation in whom elevated IGF-1 levels may persist for long time but likelihood of tumor regrowth is modest [1] (DR) and in patients with poorly controlled diabetes mellitus in whom SRLs may potentially worsen glucose metabolism [51–54] (DR). The gene discussed is IGF1; the disease is neoplasm.